Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'HUMAN INTERLEUKIN-2' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 370 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Schmidinger, M; Stager, G; Wenzel, C; Locker, GJ; Budinsky, AC; Brodowicz, T; Kramer, G; Marberger, M; Zielinski, CC
      Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: Results of a phase II trial

      JOURNAL OF IMMUNOTHERAPY
    2. Morecki, S; Yacovlev, E; Gelfand, Y; Uzi, I; Slavin, S
      Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma

      JOURNAL OF IMMUNOTHERAPY
    3. Cunningham-Rundles, C; Bodian, C; Ochs, HD; Martin, S; Reiter-Wong, M; Zhuo, Z
      Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency

      CLINICAL IMMUNOLOGY
    4. Murooka, Y; Yamashita, M
      Genetic and protein engineering of diagnostic enzymes, cholesterol oxidaseand xylitol oxidase

      JOURNAL OF BIOSCIENCE AND BIOENGINEERING
    5. Atkins, MB; Dutcher, J; Weiss, G; Margolin, K; Clark, J; Sosman, J; Logan, T; Aronson, F; Mier, J
      Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part I.IL-2-based clinical trials

      MEDICAL ONCOLOGY
    6. Recchia, F; De Filippis, S; Rosselli, M; Saggio, G; Cesta, A; Fumagalli, L; Rea, S
      Phase 1B study of subcutaneously administered interleukin 2 in combinationwith 13-cis retinoic acid as maintenance therapy in advanced cancer

      CLINICAL CANCER RESEARCH
    7. Slavin, S; Nagler, A; Shapira, M; Panigrahi, S; Samuel, S; Or, A
      Non-myeloablative allogeneic stem cell transplantation focusing on immunotherapy of life-threatening malignant and non-malignant diseases

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    8. Lauerova, L; Dusek, L; Spurny, V; Simickova, M; Rovny, A; Rejthar, A; Kocak, I; Kovarik, J
      Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients

      ONCOLOGY REPORTS
    9. Afonin, PV; Fokin, AV; Tsygannik, IN; Mikhailova, IY; Onoprienko, LV; Mikhaleva, II; Ivanov, VT; Mareeva, TY; Nesmeyanov, VA; Li, NY; Pangborn, WA; Duax, WL; Pletnev, VZ
      Crystal structure of an anti-interleukin-2 monoclonal antibody Fab complexed with an antigenic nonapeptide

      PROTEIN SCIENCE
    10. Lundin, K; Leppimaki, P; Oetken, C; Nordstrom, T; Lindqvist, C
      Production and partial characterization of mouse monoclonal antibodies recognizing common cytokine receptor gamma chain (gamma(c)) of human, mouse and primate origin

      APMIS
    11. Brocardo, MG; Schillaci, R; Galeano, A; Radrizzani, M; White, V; Guerrico, AG; Santa-Coloma, TA; Roldan, A
      Early effects of insulin-like growth factor-1 in activated human T lymphocytes

      JOURNAL OF LEUKOCYTE BIOLOGY
    12. Arad, G; Hillman, D; Levy, R; Kaempfer, R
      Superantigen antagonist blocks Th1 cytokine gene induction and lethal shock

      JOURNAL OF LEUKOCYTE BIOLOGY
    13. Sosman, JA; Stiff, P; Moss, SM; Sorokin, P; Martone, B; Bayer, R; van Besien, K; Devine, S; Stock, W; Peace, D; Chen, Y; Long, C; Gustin, D; Viana, M; Hoffman, R
      Pilot trial of interleukin-1 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: Expansion of immune effectors within the stem-cell graft and post-stem-cell infusion

      JOURNAL OF CLINICAL ONCOLOGY
    14. Porrata, LF; Inwards, DJ; Lacy, MQ; Markovic, SN
      Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation

      BONE MARROW TRANSPLANTATION
    15. Liu, S; Bugos, RC; Dharmasiri, N; Su, WW
      Green fluorescent protein as a secretory reporter and a tool for process optimization in transgenic plant cell cultures

      JOURNAL OF BIOTECHNOLOGY
    16. Vogelzang, NJ; Aklilu, M; Stadler, WM; Dumas, MC; Mikulski, SM
      A phase II trial of weekly intravenous ranpirnase (Onconase (R)), a novel ribonuclease in patients with metastatic kidney cancer

      INVESTIGATIONAL NEW DRUGS
    17. Eckenberg, R; Rose, T; Moreau, JL; Weil, R; Gesbert, F; Dubois, S; Tello, D; Bossus, M; Gras, H; Tartar, A; Bertoglio, J; Chouaib, S; Jacques, Y; Alzari, PM; Theze, J
      Characterization of an IL-2 mimetic with therapeutic potential

      CELLULAR AND MOLECULAR BIOLOGY
    18. Pascual, J; Ortuno, J
      New induction therapies in renal transplantation

      MEDICINA CLINICA
    19. Deshmukh, P; Glick, RP; Lichtor, T; Moser, R; Cohen, EP
      Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice

      JOURNAL OF NEUROSURGERY
    20. Atzpodien, J; Kirchner, H; Illiger, HJ; Metzner, B; Ukena, D; Schott, H; Funke, PJ; Gramatzki, M; von Jurgensom, S; Wandert, T; Patzelt, T; Reitz, M
      IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastaticrenal cell carcinoma: long-term results of a controlled randomized clinical trial

      BRITISH JOURNAL OF CANCER
    21. Lin, HY; Mathiszik, B; Xu, B; Enfors, SO; Neubauer, P
      Determination of the maximum specific uptake capacities for glucose and oxygen in glucose-limited fed-batch cultivations of Escherichia coli

      BIOTECHNOLOGY AND BIOENGINEERING
    22. Endo, S; Yamamoto, Y; Sugawara, T; Nishimura, O; Fujino, M
      The additional methionine residue at the N-terminus of bacterially expressed human interleukin-2 affects the interaction between the N- and C-termini

      BIOCHEMISTRY
    23. Morecki, S; Slavin, S
      Toward amplification of a graft-versus-leukemia effect while minimizing graft-versus-host disease

      JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH
    24. Tagawa, M
      Cytokine therapy for cancer

      CURRENT PHARMACEUTICAL DESIGN
    25. Leshem, B; Vourka-Karussis, U; Slavin, S
      Correlation between enhancement of graft-versus-leukemia effects followingallogeneic bone marrow transplantation by rIL-2 and increased frequency ofcytotoxic T-lymphocyte precursors in murine myeloid leukemia

      CYTOKINES CELLULAR & MOLECULAR THERAPY
    26. Tjoa, BA; Salgaller, ML
      Progress in active-specific immunotherapy of brain malignancies

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    27. Mekhail, T; Wood, L; Bukowski, R
      Interleukin-2 in cancer therapy - Uses and optimum management of adverse effects

      BIODRUGS
    28. Cattan, N; Mary, D; Peleraux, A; Mari, B; Aussel, C; Rossi, B
      Prostaglandin B-2 delivers a co-stimulatory signal leading to T cell activation

      EUROPEAN CYTOKINE NETWORK
    29. Dutcher, JP; Logan, T; Gordon, M; Sosman, J; Weiss, G; Margolin, K; Plasse, T; Mier, J; Lotze, M; Clark, J; Atkins, M
      Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: A Cytokine Working Group study

      CLINICAL CANCER RESEARCH
    30. Slavin, S
      New strategies for bone marrow transplantation

      CURRENT OPINION IN IMMUNOLOGY
    31. Lin, JX; Leonard, WJ
      The role of Stat5a and Stat5b in signaling by IL-2 family cytokines

      ONCOGENE
    32. Mukherjee, S; Haenel, T; Himbeck, R; Scott, B; Ramshaw, I; Lake, RA; Harnett, G; Phillips, P; Morey, S; Smith, D; Davidson, JA; Musk, AW; Robinson, B
      Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation

      CANCER GENE THERAPY
    33. Biola, A; Pallardy, M
      Mode of action of glucocorticoids

      PRESSE MEDICALE
    34. Fong, TC; Sauter, SL; Ibanez, CE; Sheridan, PL; Jolly, DJ
      The use and development of retroviral vectors to deliver cytokine genes for cancer therapy

      CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS
    35. Negrier, S; Caty, A; Lesimple, T; Douillard, JY; Escudier, B; Rossi, JF; Viens, P; Gomez, F
      Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil

      JOURNAL OF CLINICAL ONCOLOGY
    36. Wang, W
      Lyophilization and development of solid protein pharmaceuticals

      INTERNATIONAL JOURNAL OF PHARMACEUTICS
    37. Schmidinger, M; Steger, GG; Wenzel, C; Locker, GJ; Brodowicz, T; Budinsky, AC; Wiltschke, C; Kramer, G; Marberger, M; Zielinski, CC
      Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial

      CANCER IMMUNOLOGY IMMUNOTHERAPY
    38. Hale, GA; Phillips, GL
      Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease

      CANCER TREATMENT REVIEWS
    39. Nagler, A; Or, R; Naparstek, E; Varadi, G; Slavin, S
      Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation

      EXPERIMENTAL HEMATOLOGY
    40. Nagler, A; Ackerstein, A; Or, R; Naparstek, E; Slavin, S
      Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation

      EXPERIMENTAL HEMATOLOGY
    41. Nagler, A; Slavin, S; Varadi, G; Naparstek, E; Samuel, S; Or, R
      Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma

      BONE MARROW TRANSPLANTATION
    42. Slavin, S; Or, R; Prighozina, T; Gurevitch, O; Aker, M; Panighari, S; Shapira, M; Nagler, A
      Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man

      BONE MARROW TRANSPLANTATION
    43. Dohmann, K; Wagner, B; Horohov, DW; Leibold, W
      Expression and characterisation of equine interleukin 2 and interleukin 4

      VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY
    44. Leonard, WJ; Lin, JX
      Cytokine receptor signaling pathways

      JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
    45. Leonard, WJ
      Use of chimeric receptor molecules to dissect signal transduction mechanisms

      APPLICATIONS OF CHIMERIC GENES AND HYBRID PROTEINS PT B
    46. Lewis, MS; Junghans, RP
      Ultracentrifugal analysis of molecular mass of glycoproteins of unknown orill-defined carbohydrate composition

      NUMERICAL COMPUTER METHODS, PART C
    47. Roifman, CM
      Human IL-2 receptor alpha chain deficiency

      PEDIATRIC RESEARCH
    48. Yoshida, S; Morii, K
      Serum concentrations of soluble interleukin-2 receptor in patients with malignant brain tumors

      JOURNAL OF SURGICAL ONCOLOGY
    49. Eckenberg, R; Moreau, JL; Melnyk, O; Theze, J
      IL-2R beta agonist p1-30 acts in synergy with IL-2, IL-4, IL-9, and IL-15:Biological and molecular effects

      JOURNAL OF IMMUNOLOGY
    50. Elias, L; Lew, D; Figlin, RA; Flanigan, RC; Thompson, ME; Triozzi, PL; Belt, RJ; Wood, DP; Rivkin, SE; Crawford, ED
      Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma - A southwest oncology group phase II study

      CANCER
    51. Mackinnon, S
      Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation?

      BRITISH JOURNAL OF HAEMATOLOGY
    52. van Herpen, CML; Jansen, RLH; Kruit, WHJ; Hoekman, K; Groenewegen, G; Osanto, S; De Mulder, PHM
      Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracilfor progressive metastatic renal cell carcinoma: a multicenter phase II study

      BRITISH JOURNAL OF CANCER
    53. Salek-Ardakani, S; Arrand, JR; Shaw, D; Mackett, M
      Heparin and heparan sulfate bind interleukin-10 and modulate its activity

      BLOOD
    54. Cruz, HJ; Peixoto, CM; Nimtz, M; Alves, PM; Dias, EM; Moreira, JL; Carrondo, MJT
      Metabolic shifts do not influence the glycosylation patterns of a recombinant fusion protein expressed in BHK cells

      BIOTECHNOLOGY AND BIOENGINEERING
    55. Cha, HJ; Wu, CF; Valdes, JJ; Rao, G; Bentley, WE
      Observations of green fluorescent protein as a fusion partner in genetically engineered Escherichia coli: Monitoring protein expression and solubility

      BIOTECHNOLOGY AND BIOENGINEERING
    56. Nanda, V; Liang, SM; Brand, L
      Hydrophobic clustering in acid-denatured IL-2 and fluorescence of a Trp NH...pi h-bond

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    57. Vey, N; Blaise, D; Lafage, M; Olive, D; Viens, P; Baume, D; Camerlo, J; Stoppa, AM; Gabus, R; Brandely, M; Hercend, T; Maraninchi, D
      Treatment of chronic myelogenous leukemia with interleukin-2: A phase II study in 21 patients

      JOURNAL OF IMMUNOTHERAPY
    58. Weiss, L; Reich, S; Slavin, S
      Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments

      CYTOKINES CELLULAR & MOLECULAR THERAPY
    59. Weiss, L; Reich, S; Slavin, S
      Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4(+) and CD8(+) T cells in immunotherapyfor leukemia

      CYTOKINES CELLULAR & MOLECULAR THERAPY
    60. Burke, F
      Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer

      CYTOKINES CELLULAR & MOLECULAR THERAPY
    61. Vincenti, F
      Potential of daclizumab in solid organ transplantation

      BIODRUGS
    62. Naglieri, E; Procacci, A; Galetta, D; Abbate, I; Dell'Erba, L; Colucci, G
      Cisplatin, interleukin-2, interferon-alpha and tamoxifen in metastatic melanoma. A phase II study

      JOURNAL OF CHEMOTHERAPY
    63. Bank, U; Reinhold, D; Schneemilch, C; Kunz, D; Synowitz, HJ; Ansorge, S
      Selective proteolytic cleavage of IL-2 receptor and IL-6 receptor ligand binding chains by neutrophil-derived serine proteases at foci of inflammation

      JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
    64. Clark, JI; Gaynor, ER; Martone, B; Budds, SC; Manjunath, R; Flanigan, RC; Waters, WB; Sosman, JA
      Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma

      CLINICAL CANCER RESEARCH
    65. Fan, W; Richter, G; Cereseto, A; Beadling, C; Smith, KA
      Cytokine response gene 6 induces p21 and regulates both cell growth and arrest

      ONCOGENE
    66. Guillaume, T; Rubinstein, DB; Symann, M
      Immunological recovery and tumour-specific immunotherapeutic approaches topost-autologous haematopoietic stem cell transplantation

      BAILLIERES CLINICAL HAEMATOLOGY
    67. Nemunaitis, J; Fong, T; Robbins, JM; Edelman, G; Edwards, W; Paulson, RS; Bruce, J; Ognoskie, N; Wynne, D; Pike, M; Kowal, K; Merritt, J; Ando, D
      Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma

      CANCER GENE THERAPY
    68. Modiano, JF; Ritt, MG; Wojcieszyn, J
      The molecular basis of canine melanoma: Pathogenesis and trends in diagnosis and therapy

      JOURNAL OF VETERINARY INTERNAL MEDICINE
    69. Richards, JM; Gale, D; Mehta, N; Lestingi, T
      Combination of chemotherapy with interleukin-2 and interferon alfa for thetreatment of metastatic melanoma

      JOURNAL OF CLINICAL ONCOLOGY
    70. Mross, K; Scheulen, ME; Manegold, C; Westerhausen, M; Edler, L; Becher, R
      Phase II study with interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell carcinoma - A trial of the phase II study group of the Association for Medical Oncology of the German Cancer Society

      ONKOLOGIE
    71. Wei, W
      Instability, stabilization, and formulation of liquid protein pharmaceuticals

      INTERNATIONAL JOURNAL OF PHARMACEUTICS
    72. Saraswat, V; Kim, DY; Lee, J; Park, YH
      Effect of specific production rate of recombinant protein on multimerization of plasmid vector and gene expression level

      FEMS MICROBIOLOGY LETTERS
    73. Locatelli, MC; Facendola, G; Pizzocaro, G; Piva, L; Pegoraro, C; Pallavicini, EB; Signaroldi, A; Meregalli, M; Lombardi, F; Beretta, GD; Scanzi, F; Labianca, R; Dallavalle, G; Luporini, G
      Subcutaneous administration of interleukin-2 and interferon-alpha 2b in advanced renal cell carcinoma: Long-term results

      CANCER DETECTION AND PREVENTION
    74. Lentsch, AB; Miller, FN; Edwards, MJ
      Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2

      CANCER IMMUNOLOGY IMMUNOTHERAPY
    75. Suenaga, M; Ohmae, H; Okutani, N; Kurokawa, T; Asano, T; Yamada, T; Nishimura, O; Fujino, M
      Further studies on the chemical cleavage of an N-terminal extra methioninefrom recombinant methionylated proteins

      JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1
    76. Vivancos, P; Granena, A; Sarra, J; Granena, A
      Treatment with interleukin-2 (IL-2) and interferon (IFNalpha 2b) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse

      BONE MARROW TRANSPLANTATION
    77. Oleksowicz, L; Dutcher, JP
      A phase II trial of dose-intensive interleukin-2 in metastatic renal cell carcinoma

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    78. Cha, HJ; Dalal, NG; Vakharia, VN; Bentley, WE
      Expression and purification of human interleukin-2 simplified as a fusion with green fluorescent protein in suspended Sf-9 insect cells

      JOURNAL OF BIOTECHNOLOGY
    79. Ketzinel, M; Kaempfer, R
      Cell-mediated suppression of human interleukin-2 gene expression at splicing of mRNA

      IMMUNOLOGY LETTERS
    80. Glick, RP; Lichtor, T; de Zoeten, E; Deshmukh, P; Cohen, EP
      Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2

      NEUROSURGERY
    81. Ptitsyn, LR; Smirnov, SV; Al'tman, IB; Samsonova, NN; Khodyakova, AV; Vasilenko, RN
      Production of the recombinant hIL-4 delta 2, a native isoform of the humaninterleukin-4, in Escherichia coli cells

      BIOORGANICHESKAYA KHIMIYA
    82. Kaiser, P; Mariani, P
      Promoter sequence, exon : intron structure, and synteny of genetic location show that a chicken cytokine with T-cell proliferative activity is IL2 and not IL15

      IMMUNOGENETICS
    83. Caturla, JT; Soler, RS; Larriba, JLG
      Immunological treatment of renal cancer

      MEDICINA CLINICA
    84. Vulcano, M; Galassi, N; Felippo, M; Vernava, D; Olabuenaga, S
      Interleukin-2 restores natural killer activity inhibited by sera from HIV+hemophilic patients

      MEDICINA-BUENOS AIRES
    85. Wrenshall, LE; Platt, JL
      Regulation of T cell homeostasis by heparan sulfate-bound IL-21

      JOURNAL OF IMMUNOLOGY
    86. Helfand, SC; Dickerson, EB; Munson, KL; Padilla, ML
      GD3 ganglioside antibody augments tumoricidal capacity of canine blood mononuclear cells by induction of interleukin 12

      CANCER RESEARCH
    87. Cha, HJ; Dalal, NG; Pham, MQ; Vakharia, VN; Rao, G; Bentley, WE
      Insect larval expression process is optimized by generating fusions with green fluorescent protein

      BIOTECHNOLOGY AND BIOENGINEERING
    88. Valley, U; Nimtz, M; Conradt, HS; Wagner, R
      Incorporation of ammonium into intracellular UDP-activated N-acetylhexosamines and into carbohydrate structures in glycoproteins

      BIOTECHNOLOGY AND BIOENGINEERING
    89. Misawa, S; Kumagai, I
      Refolding of therapeutic proteins produced in Escherichia coli as inclusion bodies

      BIOPOLYMERS
    90. GRAMMATIKOS SI; VALLEY U; NIMTZ M; CONRADT HS; WAGNER R
      INTRACELLULAR UDP-N-ACETYLHEXOSAMINE POOL AFFECTS N-GLYCAN COMPLEXITY- A MECHANISM OF AMMONIUM ACTION ON PROTEIN GLYCOSYLATION

      Biotechnology progress
    91. OR R; ACKERSTEIN A; NAGLER A; AMAR A; NAPARSTEK E; VARADI G; KAPELUSHNIK J; SAMUEL S; PUGATSCH T; BRAUTBAR C; SLAVIN S
      ALLOGENEIC CELL-MEDIATED AND CYTOKINE-ACTIVATED IMMUNOTHERAPY FOR MALIGNANT-LYMPHOMA AT THE STAGE OF MINIMAL RESIDUAL DISEASE AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION

      Journal of immunotherapy
    92. NISHIMURA O; SUENAGA M; OHMAE H; TSUJI S; FUJINO M
      AN EFFICIENT CHEMICAL METHOD FOR REMOVING N-TERMINAL EXTRA METHIONINEFROM RECOMBINANT METHIONYLATED HUMAN GROWTH-HORMONE

      Chemical communications
    93. WOLFANG GHI; MCCABE RD; JOHNSON DE
      TOXICITY OF SUBCUTANEOUSLY ADMINISTERED RECOMBINANT HUMAN INTERLEUKIN-2 IN RATS

      TOXICOLOGICAL SCIENCES
    94. SCHIRRMACHER V; MUERKOSTER S; UMANSKY V
      ANTAGONISTIC EFFECTS OF SYSTEMIC INTERLEUKIN-2 ON IMMUNE T-CELL-MEDIATED GRAFT-VERSUS-LEUKEMIA REACTIVITY

      Clinical cancer research
    95. BRINCHMANN JE; ROSOK BI; SPURKLAND A
      ACTIVATION AND PROLIFERATION OF CD8(-CELLS IN LYMPHOID-TISSUES OF HIV-1-INFECTED INDIVIDUALS IN THE ABSENCE OF THE HIGH-AFFINITY IL-2 RECEPTOR() T)

      Journal of acquired immune deficiency syndromes and human retrovirology
    96. FAN J; NISHANIAN P; BREEN EC; MCDONALD M; FAHEY JL
      CYTOKINE GENE-EXPRESSION IN NORMAL HUMAN-LYMPHOCYTES IN RESPONSE TO STIMULATION

      Clinical and diagnostic laboratory immunology
    97. ZEDER K; WALLER EK; REDEI I; CONNAGHAN DG; FLEMING WH; GELLER RB; HEFFNER LT; HILLYER CD; HOLDEN J; HOLLAND K; JONES W; MCCOLLUM J; MOGUL M; PHILLIPS C; RODEY G; WINGARD JR; WINTON E; YEAGER AM; DEVINE S
      IMPACT OF DONOR LYMPHOCYTE INFUSION FOR HEMATOLOGICAL MALIGNANCY RELAPSED AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION

      Cancer research, therapy & control
    98. KARAVODIN LM; ROBBINS J; CHONG K; HSU D; IBANEZ C; MENTO S; JOLLY D; FONG TC
      GENERATION OF A SYSTEMIC ANTITUMOR RESPONSE WITH REGIONAL INTRATUMORAL INJECTIONS OF INTERFERON-GAMMA RETROVIRAL VECTOR

      Human gene therapy
    99. HE YW; MALEK TR
      THE STRUCTURE AND FUNCTION OF GAMMA-C-DEPENDENT CYTOKINES AND RECEPTORS - REGULATION OF T-LYMPHOCYTE DEVELOPMENT AND HOMEOSTASIS

      Critical reviews in immunology
    100. GOMEZ J; GONZALEZ A; MARTINEZ C; REBOLLO A
      IL-2-INDUCED CELLULAR EVENTS

      Critical reviews in immunology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/08/20 alle ore 08:41:37